Manic Or Mixed Episodes In Bipolar I Disorder Therapeutics
1. Saphris patent expiration
Treatment: Method of treating schizophrenia and bipolar disorder; Use of the atypical antipsychotic asenapine for treatment of manic or mixed episodes of bipolar i disorder: maintenance monotherapy in adults
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7741358 | ALLERGAN | Crystal form of asenapine maleate |
Apr, 2026
(2 months from now) | |
| US8022228 | ALLERGAN | Crystal form of asenapine maleate |
Apr, 2026
(2 months from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US5763476 (Pediatric) | ALLERGAN | Sublingual or buccal pharmaceutical composition |
Dec, 2020
(5 years ago) | |
| US5763476 | ALLERGAN | Sublingual or buccal pharmaceutical composition |
Jun, 2020
(5 years ago) | |
|
US7741358 (Pediatric) | ALLERGAN | Crystal form of asenapine maleate |
Oct, 2026
(8 months from now) | |
|
US8022228 (Pediatric) | ALLERGAN | Crystal form of asenapine maleate |
Oct, 2026
(8 months from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Indication(I-628) | Sep 03, 2013 |
| New Indication(I-629) | Sep 03, 2013 |
| New Chemical Entity Exclusivity(NCE) | Aug 13, 2014 |
| M(M-158) | Mar 12, 2018 |
| New Patient Population(NPP) | Mar 12, 2018 |
| Pediatric Exclusivity(PED) | Sep 12, 2018 |
| New Dosing Schedule(D-166) | Jan 13, 2020 |
| New Indication(I-597) | Jan 13, 2020 |
Drugs and Companies using ASENAPINE MALEATE ingredient
NCE-1 date: 12 September, 2017
Market Authorisation Date: 12 March, 2015
Dosage: TABLET
How can I launch a generic of SAPHRIS before it's drug patent expiration?
More Information on Dosage
SAPHRIS family patents
2. Vraylar patent expiration
Treatment: Adjunctive therapy to antidepressants for the treatment of major depressive disorder; Treatment of depressive episodes associated with bipolar i disorder (bipolar depression) with cariprazine; Treatme...
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7737142 | ABBVIE | (Thio) carbamoyl-cyclohexane derivatives as D3/D2 receptor antagonists |
Sep, 2029
(3 years from now) | |
| US7943621 | ABBVIE | Salts of piperazine compounds as D3/D2 antagonists |
Dec, 2028
(2 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| USRE49110 | ABBVIE | Pharmaceutical formulations containing dopamine receptor ligands |
Jul, 2029
(3 years from now) | |
| USRE49302 | ABBVIE | Pharmaceutical formulations containing dopamine receptor ligands |
Jul, 2029
(3 years from now) | |
| USRE47350 | ABBVIE | Pharmaceutical formulations containing dopamine receptor ligands |
Jul, 2029
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Sep 17, 2020 |
| M(M-213) | Nov 09, 2020 |
| New Indication(I-798) | May 24, 2022 |
| New Indication(I-904) | Dec 16, 2025 |
Drugs and Companies using CARIPRAZINE HYDROCHLORIDE ingredient
NCE-1 date: 18 September, 2019
Market Authorisation Date: 17 September, 2015
Dosage: CAPSULE
How can I launch a generic of VRAYLAR before it's drug patent expiration?
More Information on Dosage
VRAYLAR family patents